• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    11/1/23 12:20:45 PM ET
    $FRBN
    Blank Checks
    Finance
    Get the next $FRBN alert in real time by email
    SC 13G/A 1 lf_sc13gz.htm SCHEDULE 13-G/A Schedule 13G

     

    OMB APPROVAL

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    OMB Number:3235-0145 

    Expires:Febuary 28, 2009 

    Estimated average burden
    hours per response ....10.4

     

     

    SCHEDULE 13G

    Under the Securities and Exchange Act of 1934

    (Amendment No.         1       )*

     

    Forbion European Acquisition Corp.

    (Name of Issuer)

     

    Class A ordinary shares, par value $ 0.0001

    (Title of Class of Securities)

     

    G3619H102

    (CUSIP Number)

     

     

    October 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o  Rule 13d-1(b)

    ý  Rule 13d-1(c)

    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1


     

    CUSIP No.    G3619H102

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Feis Equities LLC 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationState of Illinois 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power0 

    6.Shared Voting Power0 

    7.Sole Dispositive Power0 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    0 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9) 

    0.00% 

    12.Type of Reporting Person (See Instructions) 

    OO-Limited Liability Company 


    2


     

    CUSIP No.    G3619H102

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Lawrence M. Feis 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationU.S.A. 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power0 

    6.Shared Voting Power0 

    7.Sole Dispositive Power0 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    0 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9)  

    0.00% 

    12.Type of Reporting Person (See Instructions) 

    IN 


    3


     

    Item 1.

    The name and address of the principal executive offices of the Issuer are:

    Forbion European Acquisition Corp.

    4001 Kennett Pike, Suite 302

    Wilmington, Delaware 19807

    Item 2.

    This statement on Schedule 13G is being filed by:

    (a) Name of Person Filing 

     

    (i)Feis Equities LLC 

    (ii)Lawrence M. Feis 

     

     

     

     

     

    (b)Address: 

    The address of the business office of each of the Reporting Persons is:

     

    1740 Waukegan Road

    Suite 206

    Glenview, Illinois  60611

     

     

     

     

     

    (c)Citizenship/Place: 

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated hereto by reference for each Reporting Person.

     

    (d)Title of Class of Securities: 

    Class A ordinary shares, par value $ 0.0001 (the “Shares”)

     

    (e)CUSIP Number: 

     

    G3619H102

     

     

     


    4


    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

    (b)oBank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

    (c)oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

    (d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

    (e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

    (f)oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

    (g)oA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

    (h)oA savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)oA church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

    (j)oGroup, in accordance with §240.13d-1(b)(1)(ii)(J). 

    Item 4.  Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for each Reporting Person and incorporated by reference herein.

     

    The percentage set forth in row 11 of the cover page for each Reporting Person is based on 12,650,000 Class A ordinary shares outstanding as of October 27,2023, as reported by the Issuer in its 10-Q quarterly filing for the period ending September 30, 2023, filed with the Securities and Exchange Commission on October 30, 2023.


    5


     

    Item 5.  Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ý

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8.  Identification and Classification of Members of the Group

    Not applicable.

    Item 9.  Notice of Dissolution of Group

    Not applicable.

    Item 10.  Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:October 31, 2023 

     

     

     

     

    Date:October 31, 2023 

     

    FEIS EQUITIES LLC

    By:/s/ Lawrence M. Feis 

                Managing Member LLC

     

     

    LAWRENCE M. FEIS

    By:/s/ Lawrence M. Feis 

     


    7


     

     

    EXHIBIT INDEX

     

    Ex.

     

    Page No.

     

     

     

    A

    Joint Filing Agreement

    9


    8


     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Class A Ordinary shares of Forbion European Acquisition Corp. dated as of October 31, 2023 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    FEIS EQUITIES LLC 

    By:/s/ Lawrence M. Feis 

    Managing Member LLC 

     

     

    LAWRENCE M. FEIS 

    By:/s/ Lawrence M. Feis 

     

    Date:  October 31, 2023


    9

    Get the next $FRBN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FRBN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FRBN
    SEC Filings

    View All

    SEC Form 15-12G filed by Forbion European Acquisition Corp.

    15-12G - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/13/23 6:45:16 AM ET
    $FRBN
    Blank Checks
    Finance

    Forbion European Acquisition Corp. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure

    8-K - Forbion European Acquisition Corp. (0001874495) (Filer)

    11/1/23 5:53:05 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form 25-NSE filed by Forbion European Acquisition Corp.

    25-NSE - Forbion European Acquisition Corp. (0001874495) (Subject)

    10/31/23 5:07:48 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Forbion Growth Sponsor Feac I B.V. returned 3,373,496 units of Class A Ordinary Shares to the company (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 7:05:31 PM ET
    $FRBN
    Blank Checks
    Finance

    Forbion Growth Sponsor Feac I B.V. converted options into 1,373,496 units of Class A Ordinary Shares (SEC Form 4)

    4 - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:59:26 PM ET
    $FRBN
    Blank Checks
    Finance

    New insider Forbion Growth Sponsor Feac I B.V. claimed ownership of 2,000,000 units of Class A Ordinary Shares (SEC Form 3) (Amendment)

    3/A - Forbion European Acquisition Corp. (0001874495) (Issuer)

    10/31/23 6:12:51 PM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance

    enGene, Inc. and Forbion European Acquisition Corp. ("FEAC", Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company Developing Next-Generation Non-Viral, Locally Administered Gene Therapies

    Leading institutional investors commit $135 million USD in transaction financing, anchored by FEAC's sponsor, Forbion Growth Sponsor FEAC I B.V. (together with its parent entity Forbion Growth Opportunities Fund I Cooperatief U.A., "Forbion Growth").enGene is a clinical-stage biotechnology company developing non-viral gene therapies based on its proprietary dually derivatized chitosan ("DDX") platform that are re-dosable, manufacturable at scale and designed to be seamlessly integrated into community clinical practices across the globe.Net proceeds are expected to be used to finance enGene's operations through multiple potential value inflection milestones towards a potential Biologics Licen

    5/17/23 7:00:28 AM ET
    $FRBN
    Blank Checks
    Finance

    VectivBio Announces Results of Extraordinary General Meeting

    BASEL, Switzerland, Dec. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Wouter Joustra was elected as a new member of the Board of Directors at the Extraordinary General Meeting held on December 9, 2022. Mr. Wouter Joustra brings a breadth of capital markets and investment experience in the life sciences investment industry to VectivBio. He joined Forbion, a leading European life sciences venture capital firm, in October 2019, where he is currently General Partner. At Forbion, Mr. Joustra is responsible for deal originatio

    12/9/22 4:01:00 PM ET
    $FRBN
    $VECT
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $FRBN
    Leadership Updates

    Live Leadership Updates

    View All

    enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer

    BOSTON and MONTREAL, Sept. 7, 2023 /PRNewswire/ - enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP, MFPM as its Chief Medical Officer, effective September 19, 2023. Dr. Bryce will oversee the clin­i­cal develop­ment of EG-70, enGene's lead product candidate for non-muscle invasive bladder cancer (NMIBC), as well as the devel­op­ment strat­e­gy for enGene's ther­a­peu­tic pipeline of tissue-targeted non-viral gene therapies.

    9/7/23 7:00:00 AM ET
    $FRBN
    Blank Checks
    Finance

    $FRBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 4:55:28 PM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G filed by Forbion European Acquisition Corp.

    SC 13G - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/14/24 6:00:38 AM ET
    $FRBN
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Forbion European Acquisition Corp. (Amendment)

    SC 13G/A - Forbion European Acquisition Corp. (0001874495) (Subject)

    2/8/24 12:51:47 PM ET
    $FRBN
    Blank Checks
    Finance